Tech Company Financing Transactions
Airna Funding Round
Airna, operating out of Cambridge, secured $60 million from Forbion Capital Partners, Alexandria Venture Investments and Arch Venture Partners.
Transaction Overview
Company Name
Announced On
7/31/2024
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance its lead product candidate into clinical trials and further develop its broad pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
238 Main Street c/o Bayer Co.Lab
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
AIRNA is on a mission to transform the lives of patients with rare and common diseases by pioneering the discovery and development of RNA editing therapeutics. AIRNA's powerful and flexible RNA editing platform, RESTORE+�, is designed to restore a patient's health by creating genetic medicines for rare and common diseases. RESTORE+� is a systematic advancement of the first published ADAR platform developed by AIRNA's founders, created to maximize therapeutic properties and address novel targets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kris Elverum
Browse more venture capital transactions:
Prev: 7/31/2024: Ema venture capital transaction
Next: 7/31/2024: FleetPulse venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs